ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
12/08/2020
Voltar para busca
Dado oficial do USPTO
TARGET E*CTR
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
TARGET E*CTR
ST13
US500000077515579Classe
35, 42, 45
Pedido
77515579
Registro
3848318
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
41
Atualização mais recente
12/08/2020
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
35, 42, 45
Data de depósito
07/07/2008
Data de registro
14/09/2010
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
29/05/2020
Última transação
29/05/2020
Escritório responsável
United States Patent and Trademark Office
Código da situação
800
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
22/06/2008
Primeiro uso no comércio
22/06/2008
Código do desenho
4
Tipo de titular
16
Localização do titular
NEW YORK, NY, US
Examinador
GOODMAN, WENDY BETH
Unidade examinadora
L90
Localização atual
GENERIC WEB UPDATE
Titulares e representantes
Titulares
TARGET HEALTH, LLC
Target Health, Inc.
Representantes
Kenneth I. Kohn KOHN & ASSOCIATES PLLC
Classificação técnica
Classes Nice
Classe 35Classe 42Classe 45
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 35
Data processing services; Providing statistical information for business or commercial purposes; Business auditing services; data processing services in the biostatistics field; Performing statistical analysis for business purposes; Manufacturer representatives in the field of pharmaceuticals; development of business processes for the analysis and implementation of clinical trials dealing with pharmaceutical drug development
Classe 42
Providing online computer database for use in gathering and providing clinical trial data regarding medical and scientific research; Scientific research; Product research and development; medical and scientific research services in the field of treatment and diagnosis provided for medical service providers; Technical writing for others; Providing quality assurance services in the field of pharmaceuticals; medical and scientific research featuring troubleshooting product and process development problems dealing with safety and regulatory toxicology programs in the field of pharmaceutical drugs; Medical and scientific researchconducting clinical trials; Consultation in the fields of pharmaceutical drug development and conducting clinical trials; consultation in the fields of pharmaceutical drug developmentconsulting with sponsormedicalscientifictoxicologymanufacturing and business experts to clearly delineate development requirements and evaluate available and competitive technologies; Product development processes; Technical writing for otherswriting integrated clinical and statistical study reports and other regulatory manuscripts; compiling data in the nature of patient records via a global computer information network for research purposes in the field of medical science and medical consultancy
Classe 45
Reviewing standards and practices to assure compliance with medical and pharmaceutical laws and regulations; reviewing standards and practices to assure compliance with US Food and Drug Administration (FDA) laws and regulations; legal consulting services regarding Food and Drug law and regulation complianceconsulting in the preparation of legal negotiationsin the preparation of legal documents and forms required by the FDAin the preparation of responses to FDA questions and warning lettersthe follow-up with FDA on post application submission questionsin the preparation of meetings with legal counsel; intellectual property licensing in the fields of drugdrug productpharmaceutical and pharmaceutical products
Publicações
Histórico de despachos e eventos da marca no USPTO.
41 publicações encontradas
NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
29/05/2020
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
29/05/2020
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
29/05/2020
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
29/05/2020
E89R
TEAS SECTION 8 & 9 RECEIVED
18/03/2020
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
14/09/2019
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
17/06/2016
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
17/06/2016
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
10/06/2016
E815
TEAS SECTION 8 & 15 RECEIVED
31/03/2016
R.PR
REGISTERED-PRINCIPAL REGISTER
14/09/2010
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
10/08/2010
REGV
LAW OFFICE REGISTRATION REVIEW COMPLETED
09/08/2010
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
08/08/2010
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/07/2010
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/07/2010
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/07/2010
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
21/02/2010
GNRT
NON-FINAL ACTION E-MAILED
21/02/2010
CNRT
SU - NON-FINAL ACTION - WRITTEN
21/02/2010
SUPC
STATEMENT OF USE PROCESSING COMPLETE
08/02/2010
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
08/02/2010
IUAF
USE AMENDMENT FILED
06/01/2010
EISU
TEAS STATEMENT OF USE RECEIVED
06/01/2010
NOAM
NOA MAILED - SOU REQUIRED FROM APPLICANT
07/07/2009
PUBO
PUBLISHED FOR OPPOSITION
14/04/2009
NPUB
NOTICE OF PUBLICATION
25/03/2009
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
10/03/2009
ALIE
ASSIGNED TO LIE
09/03/2009
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/03/2009
XAEC
EXAMINER'S AMENDMENT ENTERED
07/03/2009
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
07/03/2009
GNEA
EXAMINERS AMENDMENT E-MAILED
07/03/2009
CNEA
EXAMINERS AMENDMENT -WRITTEN
07/03/2009
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
16/10/2008
GNRT
NON-FINAL ACTION E-MAILED
16/10/2008
CNRT
NON-FINAL ACTION WRITTEN
16/10/2008
DOCK
ASSIGNED TO EXAMINER
28/09/2008
MPMK
NOTICE OF PSEUDO MARK MAILED
11/07/2008
NWAP
NEW APPLICATION ENTERED
10/07/2008
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace TARGET E*CTR ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.